Antiangiogenesis - Therapeutic strategies and clinical implications for brain tumors

Journal of Neuro-Oncology

Volumn 50, Issue 1-2, 2000, Pages 189-200

  Puduvalli, V K ^a   Sawaya, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Clinical trials; Glioma; Therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIN; CELGENE; CILENGITIDE; COMBRETASTATIN; CYTOKINE; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR; IM 862; INTERLEUKIN 12; INTERLEUKIN 8; LEFLUNOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PRINOMASTAT; SCATTER FACTOR; SQUALAMINE; TANOMASTAT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CLINICAL TRIAL; DRUG TARGETING; ENDOTHELIUM; ENDOTHELIUM CELL; GLIOMA; HUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; VASCULAR SMOOTH MUSCLE;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; BRAIN NEOPLASMS; CELL HYPOXIA; CELL MOVEMENT; CLINICAL TRIALS; COLLAGEN; CYCLOHEXANES; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE THERAPY; GLIOMA; HUMANS; INTEGRINS; INTERFERONS; LYMPHOKINES; MATRIX METALLOPROTEINASES; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TIE-2; RETINOIDS; SESQUITERPENES; STILBENES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034470398     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006469830739     Document Type: Review

References (95)

1. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting
2. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor
3. Angiogenesis in brain tumors; Pathobiological and clinical aspects
4. The postnatal growth of the rat lung. I. Morphometry
5. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
6. Endothelial proliferation in tumors and normal tissues: Continuous labeling studies
7. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
8. Tumor angiogenesis: Therapeutic implications
9. Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways
10. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis
11. Role of alpha V integrins and angiogenesis during wound repair
12. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
13. New frontiers in therapy of malignant gliomas
14. Grading of astrocytomas. A simple and reproducible method
15. Vascular morphology and angiogenesis in glial tumors
16. Elevated plasma basic fibroblast growth factor in brain tumor patients
17. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
18. Angiogenesis and angiogenesis inhibition: An overview
19. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor
20. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing
21. Vascular endothelial growth factor causes endothelial proliferation after vascular injury
22. Inhibitors of angiogenesis enter phase III testing
23. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action
24. Antiangiogenic gene therapy
25. Endpoints for determination of efficacy of antiangiogenic agents in clinical trials
26. Development of angiogenesis inhibitors for cancer therapy
27. Thalidomide is an inhibitor of angiogenesis
28. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470)
29. The effect of AGM-1470 in an improved intracranial 9L gliosarcoma rat model
30. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
31. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
32. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
33. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
34. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
35. Angiostatin suppresses malignant glioma growth in vivo
36. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms
37. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
38. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms
39. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
40. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
41. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
42. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
43. Tie2, a putative protein tyrosine kinase from a new class of cell surface receptor
44. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
45. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
46. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
47. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
48. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis
49. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
50. Tumor cell invasion and angiogenesis in the central nervous system
51. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas
52. Expression of tissue inhibitors of metalloproteinases: Negative regulators of human glioblastoma invasion in vivo
53. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
54. Marimastat (BB2516): Current status of development
55. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
56. Role of integrins in cancer: Survey of expression patterns
57. Definition of two angiogenic pathways by distinct alpha V integrins
58. Integrins, angiogenesis and vascular cell survival
59. Requirement of vascular integrin alpha V beta 3 for angiogenesis
60. An antagonist of integrin alpha V beta 3 prevents maturation of blood vessels during embryonic neovascularization
61. The alpha V beta 3 integrin 'vitronectin receptor'
62. Expression of integrin alpha V beta 3 in small blood vessels of glioblastoma tumors
63. Antiintegrin alpha V beta 3 blocks human breast cancer growth and angiogenesis in human skin
64. Novel small molecule alpha V integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
65. Stepwise in vitro affinity maturation of Vitaxin, an alpha V beta3-specific humanized mAb
66. A novel disintegrin salmosin inhibits tumor angiogenesis
67. Inhibition of angiogenesis in vitro and in vivo: Comparison of the relative activities of triflavin, an Arg-Gly-Asp containing peptide and anti-alpha V beta 3 integrin monoclonal antibody
68. Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: Expression of ligand-induced binding site on beta 3 subunit
69. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alpha V beta 3 antagonist and inducing apoptosis
70. Reduced intimal thickening following alpha V beta 3 blockade is associated with smooth muscle cell apoptosis
71. Retinoids and human cancer
72. Inhibitory effects of retinoids on vascular endothelial growth factor production by cultured human skin keratinocytes
73. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma
74. Molecular mechanisms of retinoid action
75. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma
76. RXR agonists activate PPAR alpha-inducible genes, lower triglycerides, and raise HDL levels in vivo
77. The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin)
78. Treatment of malignant gliomas with high dose 13-cis retinoic acid
79. Fenretinide activates caspases and induces apoptosis in gliomas
80. An endotoxin-induced serum factor that causes necrosis of tumors
81. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
82. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration
83. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1
84. Cytokines modulate integrin alpha V beta 3-mediated human endothelial cell adhesion and calcium signaling
85. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis
86. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma
87. Evidence for the involvement of endothelial cell integrin alpha V beta 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma
88. An overview of the interferon system: Signal transduction and mechanisms of action
89. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
90. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells
91. Successful treatment of infantile hemangiomas with interferon-alpha-2b
92. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
93. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2
94. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
95. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy